A Study Investigating the Renal Tolerability, Efficacy, and Safety of a CNI-free Versus a Standard Regimen in de Novo Heart Transplant (HTx) Recipients

• Status: Completed
• Trial end date: 2017-03-06
• Target enrollment: 0
• Participant gender: All

Summary

This study will assess whether a calcineurin inhibitor (CNI)-free regimen with everolimus and mycophenolic acid is associated with a better renal outcome as compared to the standard regimen containing cyclosporine A (which belongs to the class of CNIs) and everolimus; while both treatments are expected to be comparable with respect to efficacy.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Novartis Pharmaceuticals
• Treatments: Cyclosporine; Cyclosporins; Everolimus; Mycophenolate mofetil; Mycophenolic Acid; Sirolimus; Tacrolimus

Criteria

Inclusion criteria:

• Heart transplantation, 3 months prior to enrollment

• Patients have to receive an immunosuppressive regimen with Sandimmun® Optoral, Certican® and corticosteroids

• Sufficient graft function

• Sufficient renal function

• Females capable of becoming pregnant must have a negative serum pregnancy test within 7 days prior to or at baseline, and are required to practice an approved method of birth control for the duration of the study and for a period of 6 weeks following discontinuation of study medication, even where there has been a history of infertility

Exclusion criteria:

• Multi-organ recipients, re-transplantation, or previous transplant with any other organ.

• Patients who are recipients of A-B-O incompatible transplants

• Cold ischemia time >6 hours

• Historical or current peak PRA of > 25% at time of transplantation

• Already existing antibodies against the HLA-type of the receiving transplant Other protocol-defined inclusion/exclusion criteria may apply